Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RadnostixINIS -6.22% 3-1 Month Momentum % is -20.11% as of Aug. 18, 2026. The stock has 4 warning signs investors should review. Among 1,027 Drug Manufacturers companies, Radnostix ranks worse than 80.43% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-18), Radnostix's 3-1 Month Momentum % is -20.11%.
The industry rank for Radnostix's 3-1 Month Momentum % or its related term are showing as below:
INIS's 3-1 Month Momentum % is ranked worse than 80.43% of 1027
companies
in the Drug Manufacturers industry
Industry Median: -5.65
vs INIS: -20.11
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Radnostix 3-1 Month Momentum % Related Terms
INIS vs RMTI, BTAI, ETST: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Radnostix's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radnostix 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Radnostix's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Radnostix's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radnostix (INIS) has a 3-1 Month Momentum % of -20.11% as of Aug. 18, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Radnostix and its competitors. According to the industry distribution chart, Radnostix ranks #826 out of 1027 companies in the Drug Manufacturers industry, placing it in the top 80.4%.
Is Radnostix's 3-1 Month Momentum % too high?
Radnostix's current 3-1 Month Momentum % is -20.11%. Based on the distribution chart, Radnostix ranks #826 out of 1027 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Radnostix's 3-1 Month Momentum % compare to RMTI and BTAI?
According to the Drug Manufacturers industry distribution chart, Radnostix ranks #826 out of 1027 companies for 3-1 Month Momentum %. This places Radnostix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Radnostix and its competitors. Radnostix's current 3-1 Month Momentum % is -20.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radnostix stock overvalued right now?
Based on GuruFocus' analysis, Radnostix (INIS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.04, compared to a current price of $0.06 — trading 58.3% above its estimated fair value. The current 3-1 Month Momentum % is -20.11%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Radnostix (INIS), the current 3-1 Month Momentum % is -20.11% as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Radnostix Inc manufactures a wide range of radioisotope-focused products used in a variety of medical and industrial applications. The company produces generic sodium iodide I-131 drug product, produces a variety of cobalt-60 products, and is in development to manufacture and sell medical devices for the nuclear medicine industry. Its business consists of five reportable segments, which include: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The majority of the revenue is derived from the Theranostics Products segment, which produces and distributes various isotopically pure radiopharmaceuticals, APIs, and radiochemicals for medical, industrial, and research applications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INIS has been successfully added to your 
